Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) just unveiled an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has established a Nomination Committee to improve its corporate governance structure. This committee is responsible for the selection and appointment of directors and senior management, aiming to optimize board composition and enhance decision-making processes.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative cancer immunotherapy products. The company aims to enhance cancer treatment through its specialized therapies, targeting a significant market in oncology.
Average Trading Volume: 5,194,140
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.61B
Learn more about 1541 stock on TipRanks’ Stock Analysis page.